The premium GLP-1 companion. Tesamorelin targets visceral fat while Sermorelin preserves lean muscle and addresses skin laxity — designed specifically for women navigating body recomposition.
The Recomposition Protocol combines two growth hormone-axis peptides with complementary mechanisms. Tesamorelin is an FDA-approved GHRH analogue with a specific clinical indication for visceral fat reduction. Sermorelin works alongside it to support lean muscle preservation, metabolic efficiency, and overnight cellular repair — including addressing the skin laxity that often accompanies significant weight loss.
Tesamorelin stimulates growth hormone release with a particular affinity for reducing visceral adipose tissue (the fat stored around the organs). Sermorelin acts as a broader GHRH stimulus, supporting the full range of GH-mediated benefits including lean mass preservation, sleep architecture, and skin quality. Together they create a synergistic effect on body composition that neither achieves alone.
Women currently on or recently completing a GLP-1 protocol (semaglutide or tirzepatide), or those focused on body recomposition, visceral fat reduction, and lean muscle preservation.
Many patients use The Recomposition Protocol alongside GLP-1 medications. Your Lustre provider will review your current medications during intake and confirm compatibility before prescribing.
The opposite — muscle preservation is one of the primary goals of this stack. Sermorelin specifically supports lean mass, counteracting the muscle loss that can accompany GLP-1-driven weight reduction.
Measurable changes in body composition typically appear after 8–12 weeks. Visceral fat reduction is gradual and cumulative — most patients see the clearest results at the 4–6 month mark.
Yes — this protocol typically requires baseline IGF-1 levels before your provider can prescribe. We order labs to your nearest LabCorp or you can upload a recent panel.
Compounded peptides are prescribed off-label for wellness, performance, and recovery goals under the supervision of a licensed medical provider. They are not intended to diagnose, treat, cure, or prevent any disease.
All peptides dispensed by Lustre Health are prescription-only medications requiring a valid prescription from a licensed provider.
Compounded medications are not FDA-approved drug products. They are prepared by state-licensed 503A compounding pharmacies under USP Chapter 797 standards.
Peptides may interact with insulin, hormone therapies, and immunosuppressants. Disclose all medications to your provider.
Subcutaneous injection. Full training provided with your first shipment.